| Document |
Document Title |
|
WO/2023/150186A1 |
Disclosed herein are compounds of Formula (A), or a pharmaceutically acceptable salt thereof, which inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα). These compounds are useful in the treatment of proliferative ...
|
|
WO/2023/150526A1 |
Arylsulfonamides of 5-substituted octahydrocyclopenta[c]pyrroles, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatr...
|
|
WO/2023/148129A1 |
The present invention relates to compounds of formula (Ia), (Ia), wherein R2, M1, M2, M3, Q1 and Q2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of usin...
|
|
WO/2022/178540A9 |
The present disclosure relates methods for treating skin disorders caused by an immune deficiency with topical formulations comprising ethyl (R)-4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,
3-b]pyridine-5-carboxylate (Compoun...
|
|
WO/2023/148501A1 |
The present invention relates to compounds of formula (I) that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to p...
|
|
WO/2023/150525A1 |
Arylsulfonamides of 4-substituted-piperidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatric disorders such a...
|
|
WO/2023/148368A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and ...
|
|
WO/2023/150540A1 |
The invention provides metal chelating agents and metal complexes of these agents of use in therapeutic and diagnostic applications.
|
|
WO/2023/150681A1 |
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
|
|
WO/2023/150793A1 |
The present disclosure relates to compounds that inhibit malic enzyme 1. The disclosure further relates to methods of treating cancers mediated by malic enzyme 1.
|
|
WO/2023/148369A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and ...
|
|
WO/2023/150601A2 |
Some embodiments of the disclosure include disclosed compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain ...
|
|
WO/2023/150203A1 |
Provided herein are compounds that selectively inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the...
|
|
WO/2023/143147A1 |
Provided in the present invention are pyridazopyridone compounds, a pharmaceutical composition thereof, and the use thereof. Specifically, the compounds have structures as shown in formula (I). The compounds can interfere with the intera...
|
|
WO/2023/143249A1 |
Disclosed in the present invention are a compound that inhibits MALT1 and promotes the degradation of MALT1 by means of recruiting E3 ubiquitin ligase, and the use of the compound in the preparation of a drug for treating related disease...
|
|
WO/2023/142128A1 |
Disclosed in the present invention is a method for synthesizing a 2-phenyl-5-benzyl-imidazo[1,2-a]pyridine compound. By using a compounded nickel (II) complex having the molecular formula of Ni[P(OEt)3]{[RNC(CH3)C(CH3)NR]C}Br2 (R being 2...
|
|
WO/2023/147344A1 |
The present disclosure provides compounds of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of inhibiting isocitrate dehydrogenase 1 (ID...
|
|
WO/2023/143344A1 |
Disclosed is a novel EGFR inhibitor. Specifically, the present invention relates to a compound represented by general formula (1) and a preparation method therefor, as well as a use of the compound represented by general formula (1) and ...
|
|
WO/2023/146957A1 |
Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
|
|
WO/2023/143501A1 |
Provided are a compound possessing the structure of formula (I) and having excellent Wnt pathway inhibitory activity, or a pharmaceutically acceptable salt, an isotope derivative, or a stereoisomer thereof. Further provided are a prepara...
|
|
WO/2023/143282A1 |
The present application relates to the field of pharmaceutical chemistry, provides a hydrazino group-containing compound, specifically relates to a compound of formula (I-A), a pharmaceutically acceptable salt thereof, a pharmaceutical c...
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2023/143352A1 |
Disclosed are a nitrogen-containing heterocyclic compound, a preparation method therefor, and a use thereof. Provided is a nitrogen-containing heterocyclic compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a s...
|
|
WO/2023/142857A1 |
Disclosed in the present invention is a preparation method of Rimegepant. Specifically, the preparation method comprises the following steps: 1) reacting a compound of formula (III) with a compound of formula (IV) in a solvent 1, in the ...
|
|
WO/2023/143514A1 |
The present invention relates to a propylene ketone-containing bioinhibitor, a preparation method therefor, and a use thereof. In particular, the present invention relates to the compound represented by each of the general formulas or a ...
|
|
WO/2023/143356A1 |
Disclosed are a methionine adenosyltransferase (MAT) 2A inhibitor represented by formula (I), a preparation method for the inhibitor, a pharmaceutical composition comprising same, and a medical use thereof. The compound has excellent MAT...
|
|
WO/2023/143589A1 |
The present invention relates to a compound represented by formula (I), or an isomer, isotope derivative, polymorph, prodrug thereof, or a pharmaceutically acceptable salt or solvate thereof: wherein R1, R2, R3a, R3b, R3c, R3d, W1, W2, G...
|
|
WO/2023/143236A1 |
Disclosed are a 2H-indazole-7-formamide compound, a preparation method, a pharmaceutical composition, and an application. The structure of the compound is represented by formula (I), and comprises an isomer or pharmaceutically acceptable...
|
|
WO/2023/141866A1 |
The present invention comprises compounds of Formula (I). Wherein: R 1, R 2, R 3, R 4 and R 5 are defined in the specification, and methods of treating or ameliorating a syndrome, disorder or disease described herein by administration of...
|
|
WO/2023/143520A1 |
Described herein are ENPP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with ENPP1.
|
|
WO/2023/143576A1 |
Disclosed are a crystalline form or an amorphous form of a macrocyclic compound or a salt or solvate thereof, as well as a preparation method therefor and an application thereof. The structure of the macrocyclic compound is represented b...
|
|
WO/2023/144793A1 |
The present invention relates to compounds of formula (I), that possess DNA polymerase theta (POLQ) enzyme inhibitory activity, methods for their preparation, pharmaceutical compositions containing them, and their use in the treatment or...
|
|
WO/2023/146990A1 |
Provided are compounds of Formula (A) and Formula (I): (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions, processes of preparing and methods of treating thereof; wherein Ring A, RB, Ring B, R1, R2 and n ...
|
|
WO/2023/146987A1 |
Provided are compounds of Formula (A): Formula (A); and pharmaceutically acceptable salts thereof, and pharmaceutical compositions, processes of preparing and methods of treating thereof; wherein Ra, Ra', Ring A, Ring B, and R1 are as de...
|
|
WO/2023/143389A1 |
The present disclosure relates to a fused heterocyclic compound, a preparation method therefor, and a medical application thereof. Specifically, the present disclosure relates to a fused heterocyclic compound represented by general formu...
|
|
WO/2023/143034A1 |
The present invention relates to a pyridoimidazole derivative, a preparation method therefor and an application thereof. The compound has the structure as shown in formula (I) or (II). The present invention also relates to a preparation ...
|
|
WO/2023/143546A1 |
The present invention provides compounds having a structure of formula I and excellent Wnt pathway inhibitory activity, or pharmaceutically acceptable salts, isotope derivatives, and stereoisomers thereof. The present invention also prov...
|
|
WO/2023/144559A1 |
The present invention relates to compounds of formula I shown below: wherein R1, R4, R5 and R6 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceuti...
|
|
WO/2023/143393A1 |
Disclosed are a tricyclic compound, and a preparation method therefor and the use thereof. The tricyclic compound has a structure as shown in formula I, and can be used for treating various mental diseases and neurodegenerative diseases ...
|
|
WO/2023/144160A1 |
The invention provides new heterocyclic compounds having the general formula (I) wherein A and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the comp...
|
|
WO/2023/146511A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating diseases. Specific diseases include those that are mediated by YAP/TAZ or those that are modulated by the interaction be...
|
|
WO/2023/147312A1 |
Compounds and methods of using the same for treating conditions alleviated by AMPK activation are provided.
|
|
WO/2023/143312A1 |
Disclosed are a nitrogen-containing heterocyclic compound as represented by formula I, and a preparation method therefor and the use thereof. The compound as represented by formula I, and a stereoisomer thereof or a pharmaceutically acce...
|
|
WO/2023/147015A1 |
The invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and associated methods of treating cancer.
|
|
WO/2023/141852A1 |
Disclosed are compounds represented by formula 1a or formula 1b, and respective optical isomers, prodrugs, or pharmaceutically acceptable salts, and pharmaceutical compositions thereof, and the use thereof in the preparation of CDK2 inhi...
|
|
WO/2023/142231A1 |
A preparation method for C3-alkylated indole, in which elemental iodine is used as a catalyst, silane is used as a reducing agent and a carbonyl compound is used as an alkylation reagent, and the C3-alkylated indole is prepared under mil...
|
|
WO/2023/146991A1 |
Provided are compounds of Formula (I): (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions, processes of preparing and methods of treating thereof; wherein Ring A, Ring B, X, R1, R2 and n are as defined he...
|
|
WO/2023/143370A1 |
The present invention relates to a compound represented by general formula (I), or stereoisomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or eutectic crystals thereof, an intermediate the...
|
|
WO/2023/147418A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, togeth...
|
|
WO/2023/143210A1 |
The present invention provides phthalazinone compounds, a preparation method therefor, a pharmaceutical composition containing the phthalazinone compounds and the uses thereof. Specifically, the compounds have a structure as shown in for...
|
